Bayer, Loxo Next-Generation TRK Inhibitor Shows Promising Activity in AACR Study
ATLANTA (GenomeWeb) – A next-generation TRK inhibitor has yielded promising early results in cancer patients with NTRK gene fusions who had become resistant to other drugs that block the TRK protein.
At the annual meeting of the American Association for Cancer Research this week, David Hyman, chief of the early drug development service at Memorial Sloan Kettering Cancer Center, reported data that showed the next-generation TRK inhibitor is safe and has potential as an option for patients with advanced solid tumors who have stopped responding to another TRK inhibitor. "We are hopeful that LOXO-195 will provide continuum of care for patients," Hyman said at the meeting.